Accueil / Communiqués / Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wednesday, January 2nd 2019 at 9:05pm UTC

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Akebia
Therapeutics
, Inc. (Nasdaq: AKBA), a biopharmaceutical company
focused on the development and commercialization of therapeutics for
patients with kidney disease, granted six newly-hired employees options
to purchase an aggregate of 45,150 shares of Akebia’s common stock on
December 31, 2018, as inducements material to each such employee’s
entering into employment with Akebia. The options were granted in
accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $5.53 per share, which is equal to
the closing price of Akebia’s common stock on the grant date. Each stock
option vests over four years, with 25% of the shares vesting on the
first anniversary of the grant date and the remaining 75% of shares
vesting quarterly thereafter, in each case, subject to the new
employee’s continued service with the company. Each stock option has a
10-year term and is subject to the terms and conditions of the company’s
Inducement Award Program and a stock option agreement covering the grant.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical
company focused on the development and commercialization of therapeutics
for patients with kidney disease. The company was founded in 2007 and is
headquartered in Cambridge, Massachusetts. For more information, please
visit our website at www.akebia.com,
which does not form a part of this release.

Contacts

Argot Partners
Melissa Forst / Maghan Meyers
(212) 600-1902

Source: Akebia Therapeutics


Voir aussi

Fishawack poursuit son développement d’une offre de services hors pair avec l’acquisition de Dudnyk

Wednesday, March 20th 2019 at 9:25pm UTC KNUTSFORD, Angleterre–(BUSINESS WIRE)– Fishawack, une importante société experte …